HCPCS code J2440: Papaverine HCl injection billing guide

Key takeaways

HCPCS code J2440 covers an injection of papaverine hydrochloride, up to 60 mg per billing unit.

Medicare Part B covers J2440 when a clinician administers it and papaverine is absent from the current self-administered drug (SAD) exclusion list.

Each unit covers up to 60 mg, so a 90 mg dose bills as two units. A 30 mg dose still bills as one.

The 11-digit NDC must accompany J2440 on the claim, in Box 24A on a CMS-1500 or the revenue code 636 line on a UB-04.

Pabau’s claims management tools track J code submissions, NDC data, and unit counts for practices administering injectable drugs.

HCPCS code J2440 is the billing code for an injection of papaverine hydrochloride (papaverine HCl), up to 60 mg per unit. It is a HCPCS Level II code maintained by the Centers for Medicare and Medicaid Services (CMS).

Physicians, outpatient facilities, and billing teams use it to report the drug itself, separately from the code for administering it. J codes exist because a CPT code alone cannot carry the drug, its strength, and the billable quantity.

J2440 quick-reference table

What drug does J2440 represent?

Papaverine hydrochloride is a vasodilator and antispasmodic agent derived from opium alkaloids, though it lacks narcotic activity. Its primary clinical role is relaxing smooth muscle in blood vessels and other hollow organs.

Its labeled and clinical uses fall into four groups. Verify the specific labeled indications against current FDA drug labeling before you document medical necessity.

• Vascular surgery: Prevents arterial spasm during open or endovascular procedures
• Erectile dysfunction diagnostics: Intracavernosal injection to assess vascular response
• Vasospasm management: Used in select peripheral vascular and cerebrovascular contexts
• Combination therapy: Often combined with phentolamine (papaverine-phentolamine mixture) for erectile dysfunction treatment

The 60 mg per-unit descriptor is the maximum billable dose per unit, not the typical clinical dose. Many administrations fall below 60 mg, which is a frequent source of overbilling errors.

Medicare coverage for HCPCS code J2440

Medicare Part B covers injectable drugs, including J codes, when a practice bills them incident-to a physician’s service. That applies in a non-facility office, place of service 11. Incident-to billing does not apply in a hospital outpatient department (place of service 22).

In that setting, the facility bills the drug under the Outpatient Prospective Payment System, and payment runs through the relevant APC. Coverage for HCPCS code J2440 depends on three conditions being met at once.

• The drug must be administered by a qualified healthcare professional, not self-administered by the patient
• Medical necessity must be documented and the indication must be a covered service under Medicare
• The drug must not appear on the current self-administered drug (SAD) exclusion list maintained by CMS

Reimbursement for J2440 under Medicare Part B uses the Average Sales Price (ASP) methodology. CMS publishes updated ASP drug pricing files quarterly, and the payment rate equals ASP plus 6% in a physician office.

Rates change every quarter. Verify the current one with the CMS Physician Fee Schedule lookup tool before you quote expected reimbursement to patients or practice leadership.

When the payment on a papaverine line comes in short, read the remittance advice codes before rebilling. They separate a payer-driven adjustment from a documentation problem or a change in SAD list status.

Self-administered drug exclusion and J2440

The self-administered drug (SAD) exclusion list is the most important coverage hurdle for any J code biller. CMS maintains this list under Medicare Coverage Database Article A53032. It names the injectable drugs excluded from Part B coverage because patients typically self-administer them outside a clinical setting.

Papaverine injection is generally administered by a clinician in an office or outpatient setting, which supports coverage eligibility. Billing teams should still check SAD list status before each submission, because CMS updates the list without a prominent announcement.

Absence from the SAD list does not guarantee coverage on its own. Medical necessity documentation is a separate requirement, and a payer can deny the line on that basis alone.

How to bill J2440: Step-by-step guide

Accurate J2440 billing depends on four checks before the claim leaves the practice. Those are the unit calculation, the place of service code, the NDC, and the supporting documentation. A payer checks each one separately, so a single error is enough to stop the line.

Units and dosage billing for J2440

Each unit of J2440 covers up to 60 mg of papaverine HCl. Bill one unit for any dose up to 60 mg. For doses exceeding 60 mg, bill additional units based on the total administered dose.

Modifiers commonly used with J2440

Modifiers for J2440 depend on the payer, place of service, and route of administration. The following modifiers are the most frequently applicable.

• JA: Administered intravenously. Required by many MACs and commercial payers to distinguish IV administration from other routes.
• JB: Administered subcutaneously. It does not cover an intracavernosal or intra-arterial route, so check the payer’s guidance for those.
• 59: Distinct procedural service. Apply when J2440 is billed alongside a procedure code and bundling edits would otherwise combine them.
• GK: Reasonable and necessary item or service associated with a GA or GZ modifier claim. Relevant when an ABN has been issued.

Confirm modifier requirements against your MAC’s local coverage articles and the payer’s billing guidelines, since J code rules vary by jurisdiction. Claims management software with built-in modifier validation catches the claim that passes front-end edits and then fails at the payer.

ICD-10 diagnosis codes paired with J2440

Pairing J2440 with the correct ICD-10-CM diagnosis code is a medical necessity requirement, not a formality. Payers read the diagnosis code to decide whether the drug administration suits the documented clinical condition.

A mismatch between the drug’s documented use and the submitted code is a straightforward denial reason. Build the pairing into your charge capture template, and check each candidate against the current ICD-10-CM codes before the claim goes out.

These pairings reflect common clinical use cases. Select the diagnosis code from the documented findings in the patient’s record, not from a pre-built list. Then check that the payer accepts it under its current local coverage determination (LCD).

Documentation requirements for J2440 claims

Incomplete documentation is the second most common reason J code claims are denied, after SAD list issues. An injectable drug needs records that go beyond a standard visit note. Each element below is reviewable on its own at audit.

• Physician order: A signed order specifying papaverine HCl, the dose, route, and date of administration
• Administration record: Documentation confirming the drug was administered by a qualified clinician (not self-administered)
• Medical necessity statement: A clinical note linking the papaverine injection to the documented diagnosis and explaining why the drug was clinically indicated
• NDC number: The 11-digit National Drug Code for the specific papaverine product administered (see NDC reporting section below)
• Lot number and expiration date: Required by many MACs and commercial payers; include in the administration record

For Medicare claims, the documentation must be retained and producible on request for at least seven years. A well-built superbill captures the drug, dose, route, NDC, and ordering physician at the point of care. That is what prevents the scramble for missing records once an auditor asks.

NDC reporting requirements for J2440

Medicare and most Medicaid programs require the 11-digit NDC to be reported alongside J2440 on drug claims. The NDC identifies the exact manufacturer, product, and package size of the papaverine vial administered. Reporting a J code without the required NDC is a claim edit that results in rejection at the clearinghouse or denial at the payer.

• On CMS-1500 claims: Report the NDC in Box 24A with the N4 qualifier. Add the 11-digit NDC and the unit of measure (UN for each unit)
• On UB-04 claims: Report the NDC in the revenue code 636 line using the same N4 qualifier and unit format
• Convert the administered volume (mL) to NDC units using the package’s stated concentration to confirm the NDC quantity matches the dose billed in J2440 units

NDC requirements vary by MAC jurisdiction and payer, so confirm the current reporting rules before you finalize a claim template. A wrong digit count or a missing N4 qualifier comes back as a format error, not a coverage denial. That distinction matters, because the fix is a corrected claim rather than an appeal.

J2440 in hospital outpatient vs. physician office settings

Where the drug is administered determines how J2440 is paid, not just which claim form is used. The billing rules, the payment methodology, and the documentation requirements all differ between a physician office (POS 11) and a hospital outpatient department (POS 22).

Outpatient hospital billing teams should confirm whether papaverine is packaged into the relevant APC before building J2440 into charge capture. A packaged drug still needs the NDC and the unit count on the line, even where it earns no separate payment. Physician practices administering papaverine in an office setting have a cleaner path to separate reimbursement.

How Pabau keeps J2440 claims accurate

A papaverine claim is usually assembled from three places. The dose sits in the clinical note. The NDC sits on the vial or the supplier invoice. The unit count is worked out later by whoever raises the charge.

Pabau, practice management software for private practices, keeps those pieces in one patient record. The clinician charts the drug, dose, and route at the point of administration. The charge is raised from that entry rather than rebuilt from memory.

Claims then go out from the same system. A J2440 line missing its NDC, or carrying a unit count the note does not support, is caught before submission. Your billers spend their time on the claims that genuinely need a decision.

Manage injectable drug billing without the guesswork

Pabau’s claims management tools help practices track HCPCS J code submissions, flag modifier errors, and keep NDC reporting accurate across every injectable drug claim.

Book a demo

Conclusion

J2440 rarely carries much money on a single claim, which is why its errors survive so long. A wrong unit count or a stale NDC gets copied forward from a claim template until a payer stops paying. By then the same mistake sits on months of submitted lines.

So treat the unit math, the NDC, and the place of service as claim-level checks rather than a coding habit. Re-check SAD list status each quarter, and papaverine stops appearing in your denial reports.

Pabau keeps drug administration, NDC data, and claim submission in one record, so the J2440 line matches the note behind it. Book a demo to see how it handles injectable drug billing from administration through to payment.

Continue your research

Need to understand how clearinghouses process J code claims? Medical claims clearinghouse explained covers how claim routing, edits, and rejections work before a claim reaches the payer.

Want to know which data elements payers validate? Understanding the 837 electronic claim file walks through the fields that carry your drug code, units, and NDC.

Seeing repeat denials on injectable drug claims? Denial management in healthcare shows how to work a denial back to its cause instead of resubmitting blind.

Preparing for an audit of your J code claims? Medical billing compliance sets out the records a payer expects to find on a drug administration.

Building a tighter billing workflow for your practice? Revenue cycle management guide walks through how to structure billing from charge capture to payment posting.

Frequently asked questions